Satellos Bioscience Inc. (MSCLF)
Satellos Bioscience Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Toronto, ON, CA. The stock last traded at $6.25, up 11.81% on the session, giving a market capitalisation of $96.6M. On trailing twelve-month figures it carries a trailing P/E of -0.72, a net margin of 0.0%. Its beta of 0.71 implies it has historically moved less than the broad market.
Satellos Bioscience Inc., a company dedicated to regenerative medicine, focuses on pioneering treatments for various degenerative muscle conditions. A cornerstone of their research is a leading program aimed at developing an orally administered drug. This therapeutic seeks to rectify muscle stem cell polarity, which in turn is intended to restore the body's natural processes for muscle repair and regeneration. The enterprise was founded in 2012 and operates from its primary offices located in Toronto, Canada.
Satellos Bioscience Inc. is most often compared with the following Healthcare names: